All the statements are True regarding Selexipag except?
**Core Concept**
Selexipag is a selective IP receptor agonist used in the treatment of pulmonary arterial hypertension (PAH). It works by activating the IP receptor, which leads to vasodilation and reduced vascular resistance in the pulmonary arteries.
**Why the Correct Answer is Right**
Selexipag has a unique mechanism of action that involves the activation of the IP receptor, which is a G-protein coupled receptor. This activation leads to an increase in cyclic AMP (cAMP) levels within the vascular smooth muscle cells, resulting in vasodilation and reduced pulmonary vascular resistance. Selexipag has been shown to improve exercise capacity and delay disease progression in patients with PAH.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because Selexipag is not a phosphodiesterase-5 (PDE-5) inhibitor, unlike other PAH medications such as Sildenafil.
**Option B:** This option is incorrect because Selexipag is not a prostacyclin analog, which is a different class of medication used to treat PAH.
**Option C:** This option is incorrect because Selexipag is not a calcium channel blocker, which is a different class of medication used to treat hypertension.
**Clinical Pearl / High-Yield Fact**
Selexipag is a good option for patients with PAH who have a history of liver disease, as it does not require liver enzyme monitoring.
**Correct Answer: A. Selexipag is not a phosphodiesterase-5 (PDE-5) inhibitor.**